Patient Leaflet Updated 09-Jun-2026 | Umedica Laboratories UK Limited
Ranolazine Umedica 375 mg, 500 mg and 750 mg prolonged-release tablets
Ranolazine Umedica 375 mg prolonged-release tablets
Ranolazine Umedica 500 mg prolonged-release tablets
Ranolazine Umedica 750 mg prolonged-release tablets
ranolazine
1. What Ranolazine Umedica is and what it is used for
2. What you need to know before you take Ranolazine Umedica
3. How to take Ranolazine Umedica
4. Possible side effects
5. How to store Ranolazine Umedica
6. Contents of the pack and other information
Ranolazine Umedica is a medicine used in combination with other medicines to treat angina pectoris, which is a chest pain or discomfort that you feel anywhere along the upper part of your body between your neck and upper abdomen, often brought on by exercise or too much activity.
You must talk to a doctor if you do not feel better or if you feel worse.
Talk to your doctor before taking Ranolazine Umedica:
Your doctor may decide to give you a lower dose or take other precautions if any of these apply to you.
Do not use the following medicines if you take this medicine:
Tell your doctor or pharmacist before you take Ranolazine Umedica medicine if you use:
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Ranolazine Umedica can be taken with or without food. While being treated with Ranolazine Umedica, you should not drink grapefruit juice.
You should not take Ranolazine Umedica if you are pregnant unless your doctor has advised you to do so.
You should not take Ranolazine Umedica if you are breast-feeding. Ask your doctor for advice if you are breast-feeding.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
No studies on the effects of Ranolazine Umedica on the ability to drive and use machines have been performed. Ask your doctor for advice about driving or using machines.
Ranolazine Umedica may cause side effects such as dizziness (common), blurred vision (uncommon), confusional state (uncommon), hallucination (uncommon), double vision (uncommon), coordination problems (rare), that may affect your ability to drive or use machines. If you experience these symptoms, do not drive or operate machinery until they have resolved completely.
This medicine contain lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
This medicine contains less than 1 mmol sodium (23 mg) per prolonged-release tablet, that is to say essentially ‘sodium-free’.
Always take this medicine exactly as your doctor has told you to. Check with your doctor or pharmacist if you are not sure.
Always swallow the tablets whole with water. Do not crush, suck, or chew the tablets or break them in half, as this might affect the way the medicine is released from the tablets into your body.
The starting dose for adults is one 375 mg tablet twice a day. After 2−4 weeks, your doctor may increase the dose to get the right effect. The maximum dose of Ranolazine Umedica is 750 mg twice a day.
It is important that you tell your doctor if you get side effects such as dizziness or feeling or being sick. Your doctor may lower your dose or, if this is not sufficient, stop treatment with Ranolazine Umedica.
Children and adolescents under 18 years old should not take Ranolazine Umedica.
If you accidentally take too many Ranolazine Umedica or take a higher dose than recommended by your doctor, it is important that you tell your doctor at once. If you cannot contact your doctor, go to the nearest accident and emergency department. Take along any tablets that are left, including the container and the carton, so that the hospital staff can easily tell what you have taken.
If you forget to take a dose, take it as soon as you remember unless it is nearly time (less than 6 hours) to take your next dose. Do not take a double dose to make up for a forgotten dose.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You should stop taking Ranolazine Umedica and see your doctor immediately if you experience the following symptoms of angioedema, which is a rare condition but can be severe:
Tell your doctor if you experience common side effects such as dizziness or feeling sick or vomiting. Your doctor may lower your dose or stop treatment with Ranolazine Umedica.
Other side effects you may experience include the following:
Common side effects (occur in 1 to 10 users in 100) are:
Constipation
Dizziness
Headache
Feeling sick, vomiting
Feeling weak
Uncommon side effects (occur in 1 to 10 users in 1,000) are:
Altered sensation
Anxiety, difficulty sleeping, confusional state, hallucination
Blurred vision, visual disturbance
Changes in sensation (touch or taste), tremor, feeling tired or sluggish, sleepiness or drowsiness, faint or fainting, dizziness upon standing
Dark urine, blood in urine, difficulty urinating
Dehydration
Difficulty breathing, cough, nose bleed
Double vision
Excessive sweating, itching
Feeling swollen or bloated
Hot flushes, low blood pressure
Increases in a substance called creatinine or increases in urea in your blood, increase in blood platelets or white blood cells, changes in ECG heart tracing
Joint swelling, pain in extremity
Loss of appetite and/or weight loss
Muscle cramp, muscle weakness
Ringing in the ears and/or feeling a spinning sensation
Stomach pain or discomfort, indigestion, dry mouth, or wind
Rare side effects (occur in 1 to 10 users in 10,000) are:
A lack of ability to urinate
Abnormal laboratory values for liver
Acute kidney failure
Change in sense of smell, numbness in mouth or lips, impaired hearing
Cold sweat, rash
Coordination problems
Decrease in blood pressure upon standing
Decreased or loss of consciousness
Disorientation
Feeling of coldness in hands and legs
Hives, allergic skin reaction
Impotence
Inability to walk due to imbalance
Inflammation of pancreas or intestine
Loss of memory
Throat tightness
Low level of sodium in the blood (hyponatremia) which can cause tiredness and confusion, muscle twitching, cramps, and coma.
Not known side effects (frequency cannot be estimated from the available data) are:
Myoclonus
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.
United Kingdom
or search for MHRA Yellow Card in the Google Play or Apple App Store.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on each blister strip of tablets and on the outside of the carton and bottle after EXP.
This medicinal product does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
The active substance in Ranolazine Umedica is ranolazine. Each tablet contains 375 mg, 500 mg and 750 mg ranolazine.
The other ingredients are: microcrystalline cellulose, lactose monohydrate, methacrylic acid-ethyl acrylate copolymer, sodium hydroxide pellets, hydroxypropyl methylcellulose, magnesium stearate.
Depending on the tablet strength, the tablet coatings also contain:
375mg tablet: hypromellose, titanium dioxide, lactose monohydrate, macrogol, triacetin, Indigo carmine Aluminium Lake (E132)
500 mg tablet: hypromellose, titanium dioxide, lactose monohydrate, macrogol, triacetin, iron oxide yellow (E172)
750 mg tablet: hypromellose, titanium dioxide, lactose monohydrate, macrogol, triacetin, Brilliant Blue FCF Aluminium Lake (E133)
Ranolazine prolonged-release tablets are oblong shaped tablets.
The 375 mg tablets are pale blue approx. 15.00mm x 7.20mm and are debossed with RAN375 on one side.
The 500 mg tablets are yellow approx. 16.50mmx 8.00mm and are debossed with RAN500 on one side.
The 750 mg tablets are light blue approx. 19.00mm x 9.20mm and are debossed with RAN750 on one side.
Ranolazine Umedica is supplied in cartons containing 28, 30, 56, 60 or 100 tablets in blister strip. Not all pack-sizes may be marketed.
Marketing Authorization Holder:
Manufacturer:
This medicine is authorised in the Member States of the European Economic Area under the following names:
Ranolazine Umedica 375 mg prolonged release tablets - PL 60528/0010
Ranolazine Umedica 500 mg prolonged release tablets - PL 60528/0011
Ranolazine Umedica 750 mg prolonged release tablets - PL 60528/0012
This leaflet was last revised in 05/2026
G42, The Panorama, Park Street, Ashford, Kent, TN24 8DF, UK
01332 318295
www.umedicalabsuk.com